IL6 and systemic sclerosis: Despite a great amount of preliminary preclinical data in cardiac diseases, the therapeutic use of anti-IL1 agents (as anakinra or rilonacept) have never been reported in SSc-pHI, and no large trials to support anti-IL6 therapy with tocilizumab have been performed.[37, 38, 39, 40, 41, 42]